Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ATRC US Equity

AtriCure, Inc.Health Care · Surgical & Medical Instruments & Apparatus · CIK 1323885 · FY ends Dec 31
$47.61
+1.85 (+4.04%)
USD · as of 2026-08-19 · marketstack

Legal & controls

5 of 5 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-02-19in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · We may from time to time become a party to additional legal proceedings that arise in the ordinary course of business. See Note 10 – Commitments and Contingencies to our Consolidated Financial Statements.

Item 9A · ICFR · Based on such assessment, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2025.

Item 9A · disclosure controls · Based on this evaluation, we concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s forms and rules, and the material information relating to the Company is accumulated and communicated to management, including the President and Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

2024-12-312025-02-14in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · We may from time to time become a party to additional legal proceedings that arise in the ordinary course of business. See Note 11 – Commitments and Contingencies to our Consolidated Financial Statements.

Item 9A · ICFR · Based on such assessment, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2024.

Item 9A · disclosure controls · Based on this evaluation, we concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s forms and rules, and the material information relating to the Company is accumulated and communicated to management, including the President and Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

2023-12-312024-02-16in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · We may from time to time become a party to additional legal proceedings that arise in the ordinary course of business. See Note 10 – Commitments and Contingencies to our Consolidated Financial Statements.

Item 9A · ICFR · Based on such assessment, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2023.

Item 9A · disclosure controls · Based on this evaluation, we concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s forms and rules, and the material information relating to the Company is accumulated and communicated to management, including the President and Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

2022-12-312023-02-22in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · We may from time to time become a party to additional legal proceedings that arise in the ordinary course of business. See Note 10 – Commitments and Contingencies to our Consolidated Financial Statements.

Item 9A · ICFR · Based on such assessment, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2022.

Item 9A · disclosure controls · Based on this evaluation, we concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s forms and rules, and the material information relating to the Company is accumulated and communicated to management, including the President and Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

2021-12-312022-02-17in the noteseffectiveeffectivenone in Item 9AEDGAR

Item 3 · We may from time to time become a party to additional legal proceedings that arise in the ordinary course of business. See Note 11 – Commitments and Contingencies to our Consolidated Financial Statements.

Item 9A · ICFR · Based on such assessment, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2021.

Item 9A · disclosure controls · Based on this evaluation, we concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s forms and rules, and the material information relating to the Company is accumulated and communicated to management, including the President and Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.